|
BioSpecifics Technologies |
|
|
35 Wilbur Street
Lynbrook, NY 11563-2358 USA
phone:(516) 593-7000
fax:(516) 593-7039
|
|
| Symbol |
BSTC |
| Exchange |
Nasdaq |
| Founded |
1990 |
| Employees |
39 |
|
|
| www.biospecifics.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Wound healing and tissue remodeling. |
|
| Management |
| Edwin H. Wegman, Chairman of the Board, President Thomas L. Wegman, Executive Vice President, Director |
| |
|
|
|
|
|
|
|
| Keywords |
| woundwound, woundcare |
|
|
|
| Description |
|
Biospecifics Technologies Corp. manufactures and licenses a fermentation derived enzyme named Collagenase ABC, approved by the FDA for debriding chronic dermal ulcers and severely burned areas. The Company is also developing additional products derived from this enzyme for potential use as pharmaceuticals. |
|
| Products / Services |
Collagenase Santyl? ointment contributes towards the formation of granulation tissue and subsequent epithelization of dermal ulcers and severely burned areas.
|
|
| Technology / Differentiation |
| BioSpecifics has learned how to make collagenase in a concentrated, purified form. Their proprietary bacterial collagenase dissolves only the couplings of the collagen molecule train. The collagenase produced by the body does it one coupling per train; while their bacterial collagenase dissolves the amino acid couplings at multiple sites along the collagen triple helix. Safely. |
|
| Market / Customers |
Proprietary technology used for: Dermal ulcers, Pressure sores, bedsores, Second and third degree burns, Dupuytren's Disease, Peyronie's Disease, Glaucoma, Spinal Disk Diseas.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
